Treatment of Natural Killer/T Cell Lymphoma-I/II
The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with newly diagnosed stage I/II Natural Killer (NK)/T Cell Lymphoma.
Nasal and Nasal-type NK/T-cell Lymphoma
OTHER: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|OTHER: VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|OTHER: gemcitabine,pegaspargase,cisplatin,dexamethasone|OTHER: cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|RADIATION: Radiotherapy
Progression-free survival, up to end of follow-up-phase (approximately 24 months)
Response rate, 21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles., every 6 weeks,up to completion of treatment(approximately 18 weeks )|overall survival, up to the date of death (approximately 5 years)|median survival time, 5 years
Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP. The investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment DDGP (gemcitabine，pegaspargase, cisplatin, dexamethasone) in the patients with stage I/II NK/T cell lymphoma.